USO 24197

A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor (J2N-MC-JZNX)

Disease Types: Lymphoma & Hematologic

Eligibility Requirements:

• Subjects must have a confirmed diagnosis of CLL/SLL that requires
therapy consistent with iwCLL 2018 criteria for initiation of therapy
• ECOG ≤ 2
• Part 1
• Must have known 17p deletion status by FISH
• Must have received 1-3 LOT that included a covalent BTK
inhibitor
• Part 2
• Must have 17p deletion positive disease
• Have not received prior treatment
• Subjects that received prior treatment with a BTK degrader or a
noncovalent BTK inhibitor are excluded
• Subjects with known or suspected history of central nervous system
involvement by CLL/SLL are excluded

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Newport News (Port Warwick III)
• Hampton (CarePlex)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg